Biosimulation Market Set to Reach USD 11 Billion by 2030, Expanding at a CAGR of 19%
According to Next Move Strategy Consulting, the global biosimulation market, is poised for significant growth, with projections indicating it will reach USD 11 billion by 2030. This expansion represents a compound annual growth rate (CAGR) of 19% by 2030, driven by the increasing adoption of biosimulation software and services in various industries, particularly in drug development, disease modeling, and cancer research.
Download Free Sample: https://www.nextmsc.com/biosimulation-market/request-sample
Market Definition
Biosimulation is a multidisciplinary field that uses computational models to simulate and analyze biological systems. By utilizing mathematical and computational algorithms, biosimulation allows researchers to predict the behavior of complex biological processes such as cell functions, drug interactions, and disease mechanisms. This technology is crucial for understanding disease progression, developing new treatments, and optimizing drug discovery and development. The use of biosimulation in creating models for cancer therapies and drug efficacy has gained widespread attention in recent years.
Market Dynamics and Trends
The growth of the biosimulation market is largely attributed to the increasing demand for software platforms such as Phoenix, a leading tool for reviewing new drug applications globally. Widely used by over 6,000 scientists in biopharmaceutical companies, academic institutions, and regulatory bodies, Phoenix helps streamline drug development processes.
In addition, the growing adoption of biosimulation services and software across biosimilar companies, pharmaceutical organizations, and regulatory authorities contributes significantly to market growth. Biosimulation reduces the risk of drug failure and cuts development costs, which are critical factors driving its adoption.
Despite these positive trends, the market faces challenges such as the limited understanding of biological processes, the lack of standard methodologies for biosimulation, and the high failure rate of drug development. However, the continued development of biosimulation technologies, particularly in areas such as CAR T-cell therapies for cancer treatment, presents considerable growth opportunities for the market.
Inquire Before Buying: https://www.nextmsc.com/biosimulation-market/inquire-before-buying
Market Segmentation and Scope of the Study
The biosimulation market is segmented into several categories, including type, component, application, delivery model, and end user:
- By Type: Large-scale biosimulation, Small-scale biosimulation
- By Component: Software (PK/PD modeling, toxicity prediction, molecular modeling, etc.) and Services (in-house and contract services)
- By Application: Drug development (preclinical testing, clinical trials), drug discovery (target identification & validation, lead optimization), others
- By Delivery: Subscription, Ownership
- By End User: Contract research organizations (CROs), pharmaceutical & biotechnology companies, regulatory authorities, academic & research institutes
Geographically, the market is analyzed across North America, Europe, Asia-Pacific, and the rest of the world, with North America holding a dominant share due to high adoption rates in cancer treatment research and regulatory approval of biosimulation tools.
Geographical Analysis
North America is expected to maintain its dominance in the biosimulation market during the forecast period. The region’s robust use of biosimulation technology in the treatment of cancers such as stomach, breast, and colorectal cancer plays a major role in market growth. For instance, in 2021, U.S.-based Cellworks utilized biosimulation technology to enhance cancer treatment outcomes by combining AI and precision medicine. Additionally, the U.S. FDA’s approval of biosimulation software, such as Certara’s Phoenix and Simcyp platforms, is further boosting market expansion.
In Europe, a rise in chronic diseases and cancer cases is driving the demand for biosimulation tools for drug discovery and development. The European Society for Medical Oncology reports that cancer cases in the region are increasing, which underscores the need for efficient drug development processes and predictive modeling.
Competitive Landscape
The biosimulation market is highly competitive, with key players such as Schrodinger, Simulations Plus, Certara, Genedata, and Dassault Systèmes leading the way. These companies employ strategies such as product launches, new software development, and market expansions to maintain their competitive edge.
Notable recent developments include:
- Certara’s launch of new biosimulation tools in 2022, including Immunogenicity and Vaccine Simulators, based on quantitative systems pharmacology (QSP) to aid in immuno-oncology research.
- Simulations Plus receiving a Phase II SBIR NIH grant in 2022 to advance its Biologxsym platform, which focuses on liver safety for biologics.
Conclusion
The biosimulation market is expected to continue its rapid expansion over the coming years, driven by the increasing adoption of biosimulation software and services, especially within the pharmaceutical and biotechnology sectors. The growing need for advanced modeling in drug development and cancer research presents substantial opportunities for growth.
Also, Browse Related Reports:
For more information, please contact:
Next Move Strategy Consulting
E-Mail: info@nextmsc.com
Direct: +1-217-650-7991
Website: www.nextmsc.com
Follow Us: LinkedIn | Twitter | Facebook | Instagram | YouTube
About Next Move Strategy Consulting:
Next Move Strategy Consulting is a premier market research and management consulting firm that has been committed to provide strategically analysed well documented latest research reports to its clients. The research industry is flooded with many firms to choose from, what makes Next Move different from the rest is its top-quality research and the obsession of turning data into knowledge by dissecting every bit of it and providing fact-based research recommendation that is supported by information collected from over 500 million websites, paid databases, industry journals and one on one consultations with industry experts across a diverse range of industry sectors. The high-quality customized research reports with actionable insights and excellent end-to-end customer service help our clients to take critical business decisions that enables them to move beyond time and have competitive edge in the industry.
We have been servicing over 1000 customers globally that includes 90% of the Fortune 500 companies over a decade. Our analysts are constantly tracking various high growth markets and identifying hidden opportunities in each sector or the industry. We provide one of the industry’s best quality syndicates as well as custom research reports across 10 different industry verticals. We are committed to deliver high quality research solutions in accordance to your business needs. Our industry standard delivery solutions that range from the pre consultation to after-sales services, provide an excellent client experience and ensure right strategic decision making for businesses.